182 related articles for article (PubMed ID: 26805764)
21. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.
Lee TH; Seng S; Sekine M; Hinton C; Fu Y; Avraham HK; Avraham S
PLoS Med; 2007 Jun; 4(6):e186. PubMed ID: 17550303
[TBL] [Abstract][Full Text] [Related]
22. Autocrine and paracrine functions of vascular endothelial growth factor (VEGF) in renal tubular epithelial cells.
Villegas G; Lange-Sperandio B; Tufro A
Kidney Int; 2005 Feb; 67(2):449-57. PubMed ID: 15673292
[TBL] [Abstract][Full Text] [Related]
23. The antitumor effect of a novel angiogenesis inhibitor (an octahydronaphthalene derivative) targeting both VEGF receptor and NF-κB pathway.
Watari K; Nakamura M; Fukunaga Y; Furuno A; Shibata T; Kawahara A; Hosoi F; Kuwano T; Kuwano M; Ono M
Int J Cancer; 2012 Jul; 131(2):310-21. PubMed ID: 21826646
[TBL] [Abstract][Full Text] [Related]
24. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways.
Santos SC; Dias S
Blood; 2004 May; 103(10):3883-9. PubMed ID: 14726393
[TBL] [Abstract][Full Text] [Related]
25. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
[TBL] [Abstract][Full Text] [Related]
27. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
28. Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.
Deng M; Zha J; Jiang Z; Jia X; Shi Y; Li P; Chen XL; Fang Z; Du Z; Xu B
J Transl Med; 2018 Feb; 16(1):47. PubMed ID: 29490645
[TBL] [Abstract][Full Text] [Related]
29. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
Sini P; Wyder L; Schnell C; O'Reilly T; Littlewood A; Brandt R; Hynes NE; Wood J
Clin Cancer Res; 2005 Jun; 11(12):4521-32. PubMed ID: 15958638
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
32. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
Kim DS; Franklyn JA; Boelaert K; Eggo MC; Watkinson JC; McCabe CJ
J Clin Endocrinol Metab; 2006 Nov; 91(11):4603-11. PubMed ID: 16926250
[TBL] [Abstract][Full Text] [Related]
33. Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma.
Ohba T; Cates JM; Cole HA; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
Mol Cancer Res; 2014 Aug; 12(8):1100-11. PubMed ID: 24759089
[TBL] [Abstract][Full Text] [Related]
34. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway.
Liu W; Xu J; Wang M; Wang Q; Bi Y; Han M
Int J Oncol; 2011 Nov; 39(5):1213-20. PubMed ID: 21785819
[TBL] [Abstract][Full Text] [Related]
35. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.
Graells J; Vinyals A; Figueras A; Llorens A; Moreno A; Marcoval J; Gonzalez FJ; Fabra A
J Invest Dermatol; 2004 Dec; 123(6):1151-61. PubMed ID: 15610528
[TBL] [Abstract][Full Text] [Related]
36. Stimulatory Effect of Vascular Endothelial Growth Factor on Proliferation and Migration of Porcine Trophectoderm Cells and Their Regulation by the Phosphatidylinositol-3-Kinase-AKT and Mitogen-Activated Protein Kinase Cell Signaling Pathways.
Jeong W; Kim J; Bazer FW; Song G
Biol Reprod; 2014 Mar; 90(3):50. PubMed ID: 24451985
[TBL] [Abstract][Full Text] [Related]
37. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.
Tian S; Quan H; Xie C; Guo H; Lü F; Xu Y; Li J; Lou L
Cancer Sci; 2011 Jul; 102(7):1374-80. PubMed ID: 21443688
[TBL] [Abstract][Full Text] [Related]
38. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway.
Wang Y; Deng M; Chen Q; Li Y; Guo X; Shi P; He L; Xie S; Yu L; Zhang H; Xu B
Eur J Pharmacol; 2019 Jan; 843():145-153. PubMed ID: 30423319
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.
Wey JS; Fan F; Gray MJ; Bauer TW; McCarty MF; Somcio R; Liu W; Evans DB; Wu Y; Hicklin DJ; Ellis LM
Cancer; 2005 Jul; 104(2):427-38. PubMed ID: 15952180
[TBL] [Abstract][Full Text] [Related]
40. Tissue factor pathway inhibitor-2 is upregulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells.
Xu Z; Maiti D; Kisiel W; Duh EJ
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2819-25. PubMed ID: 17023682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
